Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10021


The purpose of this study is to find out the safety and feasibility of weekly topotecan consolidation therapy in patients with ovarian cancer.

Study summary:

Patients with Stage IIIC and IV optimally-debulked ovarian cancer will be treated with 6 cycles (every 3 weeks) of carboplatin (AUC 5) and paclitaxel (175 mg/m2). Patients who demonstrate a complete clinical response to this regimen will then be treated with topotecan consolidation (4 mg/m2 weekly x 8 weeks for one cycle followed by a break in the 9th week) for a maximum of 3 cycles. Primary endpoints will be toxicity and the determination of the appropriate dose, schedule, and duration of topotecan for further consolidation trials.


Inclusion Criteria: - Patients must have a histopathologic diagnosis of epithelial ovarian cancer. - Patients must have completed front-line chemotherapy and be clinically NED (CA 125 <35, negative CT scan, negative physical exam). - Patients may have a second look laparoscopy, however, there must be no gross disease present (microscopic disease or pathologically negative). - Patients must not have had other myelosuppressive therapy within four weeks of initiating topotecan therapy. - Topotecan treatment must begin within 10 weeks following last cycle of initial chemotherapy. - Patients may have had only one prior chemotherapy regimen. Exclusion Criteria: - Patients with a concomitant malignancy other than squamous cell or basal cell skin cancer. - Patients who are pregnant or breast-feeding.

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Weekly Topotecan Therapy in Patients With Ovarian Cancer

Official Title:

A Phase II Trial of Weekly Topotecan As Consolidation Therapy in Ovarian Cancer Patients After Initial Chemotherapy

Overall Status:


Study Phase:

Phase 2



Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Weill Medical College of Cornell University

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Non-Randomized, Endpoint Classificati

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:

Overall Contact Information

Official Name:Thomas Caputo, M.D.
Principal Investigator
Weill Medical College of Cornell University

Study Dates

Start Date:February 2003
Completion Date:August 2006
Verification Date:September 2006
Last Changed Date:September 12, 2006
First Received Date:September 13, 2005

Study Outcomes

Outcome Type:Secondary Outcome
Measure:To determine the efficacy (Progression free survival) of weekly topotecan as consolidation therapy in ovarian cancer patients who are clinically NED or have microscopic disease only after first-line chemotherapy.
Safety Issues:False
Outcome Type:Primary Outcome
Measure:The objective of this study is to evaluate the safety and feasibility of weekly topotecan consolidation therapy in patients with epithelial ovarian cancer.
Safety Issues:False

Study Interventions

Intervention Type:Drug

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Weill Medical College of Cornell University

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.